TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7604754

Group type: EXPERIMENTAL
Intervention: Quinine sulphate capsule
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Quinine dihydrochloride plain tablet
Number of subjects: 6

Group type: COMPARATOR
Intervention: Quinine sulphate sugar coated tablet
Number of subjects: 6

Group type: COMPARATOR
Intervention: Quinine hydrochloride (IV infusion)
Number of subjects: 6
Study: 3075630

Group type: EXPERIMENTAL
Intervention: Pheniramine maleate (supplement) for the first 3 months
Number of subjects: 120

Group type: COMPARATOR
Intervention: Clofazimine and dapsone (control) for 12 months without supplement
Number of subjects: 120
Study: 30629121

Group type: EXPERIMENTAL
Intervention: Tai Ji Quan: Moving for Better Balance (TJQMBB)
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Multimodal exercise
Number of subjects: 670

Group type: COMPARATOR
Intervention: Stretching exercise (control)
Number of subjects: 670
Study: 28707741

Group type: EXPERIMENTAL
Intervention: Psychological counselling plus sleep adjuvant measures
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Psychological counselling alone
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Sleep adjuvant measures alone
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 74
Study: 25956819

Group type: EXPERIMENTAL
Intervention: ThuVEP
Number of subjects: 29

Group type: COMPARATOR
Intervention: TURP
Number of subjects: 29
Study: 23201969

Group type: EXPERIMENTAL
Intervention: Essentialist mind-set
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-essentialist mind-set (control)
Number of subjects: 0
Study: 22104550

Group type: EXPERIMENTAL
Intervention: Low-glycemic-index diets
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: Low-protein diets
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 932
Study: 19025407

Group type: EXPERIMENTAL
Intervention: 830-nm diode laser treatment (10 Hz, 50% duty cycle, 60 mW, 9.7 J/cm²) for 2 weeks, 10-min sessions, 5 days a week
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (sham laser treatment)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 830-nm diode laser treatment
Number of subjects: 36
Study: 16875929

Group type: EXPERIMENTAL
Intervention: 5-HTT binding in bipolar disorder subjects
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 5-HTT binding in bipolar disorder subjects with anxiety symptoms
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 5-HTT binding in bipolar disorder subjects with pathological obsessions and compulsions
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 5-HTT binding in bipolar disorder subjects with a history of suicide attempts
Number of subjects: 55

Group type: COMPARATOR
Intervention: 5-HTT binding in healthy controls
Number of subjects: 55
Study: 12616405

Group type: EXPERIMENTAL
Intervention: New special senior shoes with higher heel height
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: New special senior shoes with lower heel height
Number of subjects: 26

Group type: COMPARATOR
Intervention: Habitual shoes
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Adaptation after five weeks with new shoes
Number of subjects: 26
Study: 10720170

Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified food
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Fever prevalence
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Diarrhea prevalence
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Elevated C-reactive protein levels
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Weight at birth or at 1 month of age
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: More rapid weight gain
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Socioeconomic status
Number of subjects: 208
Study: 9445577

Group type: EXPERIMENTAL
Intervention: Zolpidem 8.03 mg
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Zolpidem 16.06 mg
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Dipotassium clorazepate 10 mg
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Dipotassium clorazepate 20 mg
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Promethazine 50 mg
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Dipotassium clorazepate
Number of subjects: 320
Study: 1548998

Group type: EXPERIMENTAL
Intervention: Exercise regimen (12 weeks, 1 hour sessions, 3 days/week: 20 min cycle exercise at 60-80% HRreserve followed by 35 min strength and flexibility training)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Counseling control condition
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Exercise regimen
Number of subjects: 37
Study: 3919975

Group type: EXPERIMENTAL
Intervention: Ingestion of food (mixed breakfast)
Number of subjects: 6
Study: 30169405

Group type: EXPERIMENTAL
Intervention: Neostigmine 20 μg/kg and atropine 10 μg/kg
Number of subjects: 85

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 85
Study: 28962662

Group type: EXPERIMENTAL
Intervention: ANTICOAGULATION CHOICE conversation tool
Number of subjects: 999

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 999
Study: 26275330

Group type: EXPERIMENTAL
Intervention: Home assessment
Number of subjects: 731

Group type: COMPARATOR
Intervention: Clinic follow-up
Number of subjects: 731
Study: 23470704

Group type: EXPERIMENTAL
Intervention: Acuity-adaptable patient room
Number of subjects: 2

Group type: COMPARATOR
Intervention: Transitional care process
Number of subjects: 2
Study: 22009803

Group type: EXPERIMENTAL
Intervention: Ceftizoxime with ampicillin
Number of subjects: 135

Group type: COMPARATOR
Intervention: Amikacin with ampicillin
Number of subjects: 135
Study: 18166839

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m2 on days 1 and 8 plus cisplatin 80 mg/m2 on day 1 (GC)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m2 on days 1 and 8 plus paclitaxel 200 mg/m2 on day 1 (GP)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m2 on days 1 and 8 plus carboplatin area under the curve 5.5 on day 1 (GCb)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with gemcitabine (all regimens)
Number of subjects: 87
Study: 16408151

Group type: EXPERIMENTAL
Intervention: Client's rating of the working alliance at 3 months and 15 months post baseline
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Case manager's rating of the working alliance at 3 months and 15 months post baseline
Number of subjects: 115
Study: 15560162

Group type: EXPERIMENTAL
Intervention: Viagra (individually adjusted dose for 6 months)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Sialis (20 mg for 6 months)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Impase (1 tablet every other day sublingually for 6 months)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Combination of PDE‐5 inhibitors (Viagra, Sialis) and Impase
Number of subjects: 218
Study: 11693769

Group type: EXPERIMENTAL
Intervention: Targeted ablation of atrial ectopic foci concentrated in the pulmonary veins
Number of subjects: 0
Study: 9038595

Group type: EXPERIMENTAL
Intervention: Brisk walking (12-month program, building up to 20.4 +/- 3.8 min/day)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 84
Study: 8477555

Group type: EXPERIMENTAL
Intervention: Oral racemic ibuprofen (400 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous racemic ibuprofen (60-minute infusion)
Number of subjects: 10
Study: 2892874

Group type: EXPERIMENTAL
Intervention: Carteolol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Metipranolol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 10
Study: 30020987

Group type: EXPERIMENTAL
Intervention: Five-week Yin yoga intervention
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Five-week intervention combining Yin yoga with psychoeducation and mindfulness (YOMI program)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (no yoga or mindfulness practice)
Number of subjects: 105
Study: 27384536

Group type: EXPERIMENTAL
Intervention: Cluster randomized designs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emergency research
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other designs
Number of subjects: 0
Study: 24554962

Group type: EXPERIMENTAL
Intervention: Pre-warmed serum (37°C)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Room temperature serum (25.5°C)
Number of subjects: 62
Study: 22854639

Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (75 µg or 3,000 IU per day)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 20231324

Group type: EXPERIMENTAL
Intervention: Sertraline plus Naltrexone (200 mg/day + 100 mg/day)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Naltrexone (100 mg/day)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Sertraline (200 mg/day)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 19278081

Group type: EXPERIMENTAL
Intervention: 2% zinc citrate fluoride dentifrice
Number of subjects: 43

Group type: COMPARATOR
Intervention: commercial fluoride dentifrice
Number of subjects: 43

Group type: COMPARATOR
Intervention: matching placebo
Number of subjects: 43
Study: 15767536

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (100 mg) every other week by intramuscular injection
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (equivalent volume) every other week by intramuscular injection
Number of subjects: 38
Study: 11729638

Group type: EXPERIMENTAL
Intervention: Orlistat (lipase inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nomma Herb's extract (CT‐II)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olestra (fat substitute)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alpha-glucosidase inhibitors (inhibitors of carbohydrate absorption)
Number of subjects: 0
Study: 9041328

Group type: EXPERIMENTAL
Intervention: Longitudinal plasma RNA levels
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Treatment groups in mean plasma RNA level
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Average change over time
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Area under the curve
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Minimum plasma RNA level
Number of subjects: 326
Study: 7523914

Group type: EXPERIMENTAL
Intervention: Chronic exposure to arsenic via drinking water (412 micrograms/l)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (drinking water with arsenic average levels of 37.2 micrograms/l)
Number of subjects: 0
Study: 3452274

Group type: EXPERIMENTAL
Intervention: Caffeine (230 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30006327

Group type: EXPERIMENTAL
Intervention: Blended care self-management program (Partner in Balance)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Waiting-list control group (usual care)
Number of subjects: 81
Study: 27213613

Group type: EXPERIMENTAL
Intervention: Lancet weight of 25 g
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lancet weight of 85 g
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lancet weight of 135 g
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lancet weight of 265 g
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (negative control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Histamine 1 mg/mL (positive control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Histamine 10 mg/mL (positive control)
Number of subjects: 20
Study: 23692706

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 4μg/kg
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control (saline placebo)
Number of subjects: 104
Study: 20932788

Group type: EXPERIMENTAL
Intervention: Mechanical pain test (pressure) at lower back, suprascapular region, and second toe.
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Thermal pain test (heat and cold) at lower back, suprascapular region, and lateral aspect of the leg.
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Cold pressor test (withdrawal time).
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Analysis of influences on pain measures (gender, age, height, weight, BMI, depression, anxiety, catastrophizing, SF-36 parameters).
Number of subjects: 300
Study: 19202157

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily (n = 118)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo (n = 116)
Number of subjects: 234
Study: 17005362

Group type: EXPERIMENTAL
Intervention: 0.03 mg/kg of etomidate (priming group)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 46
Study: 15316868

Group type: EXPERIMENTAL
Intervention: Risedronate 2.5 mg/day
Number of subjects: 547

Group type: COMPARATOR
Intervention: Etidronate 200 mg/day (intermittent treatment)
Number of subjects: 547
Study: 11736716

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (6 mg twice daily, increasing to 9 mg twice daily after 6 weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 9522321

Group type: EXPERIMENTAL
Intervention: HRT (hormonal replacement therapy) as oral or transdermal oestradiol supplemented with progestogen
Number of subjects: 706

Group type: EXPERIMENTAL
Intervention: Oral sequential oestrogen plus progestogen
Number of subjects: 706
Study: 7526126

Group type: EXPERIMENTAL
Intervention: High-monounsaturated-fat diet (H-MUFA)
Number of subjects: 15

Group type: COMPARATOR
Intervention: High-carbohydrate diet (H-CHO)
Number of subjects: 15
Study: 3047394

Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine (1.5 mg/2.5 cm2)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 29254669

Group type: EXPERIMENTAL
Intervention: IV lidocaine (1.5 mg/kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: IV morphine (0.1 mg/kg)
Number of subjects: 50
Study: 28474075

Group type: EXPERIMENTAL
Intervention: Co‐Cr alloy cast post and core restoration
Number of subjects: 97

Group type: COMPARATOR
Intervention: everStick fiber post and core restoration
Number of subjects: 97
Study: 25060683

Group type: EXPERIMENTAL
Intervention: Bupivacaine with triamcinolone (BV-TA)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Bupivacaine (BV) only
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 23237793

Group type: EXPERIMENTAL
Intervention: Cash transfer program to mothers
Number of subjects: 0
Study: 21698591

Group type: EXPERIMENTAL
Intervention: Intra-articular infiltration of 10 ml of 0.25% bupivacaine
Number of subjects: 73

Group type: COMPARATOR
Intervention: Portal infiltration of 10 ml of 0.25% bupivacaine
Number of subjects: 73

Group type: COMPARATOR
Intervention: Portal infiltration
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Intra-articular infiltration
Number of subjects: 73
Study: 18483104

Group type: EXPERIMENTAL
Intervention: Radioiodine therapy
Number of subjects: 76
Study: 22343799

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study: 16332474

Group type: COMPARATOR
Intervention: Standard pancreaticoduodenectomy (PD)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Radical pancreaticoduodenectomy (PD) with distal gastrectomy and retroperitoneal lymphadenectomy
Number of subjects: 299

Group type: COMPARATOR
Intervention: Standard pancreaticoduodenectomy (PD) for pancreatic adenocarcinoma
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Radical pancreaticoduodenectomy (PD) for pancreatic adenocarcinoma
Number of subjects: 299

Group type: COMPARATOR
Intervention: Standard resection
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Radical resection
Number of subjects: 299
Study: 12785243

Group type: EXPERIMENTAL
Intervention: Auditory cues at 115% of mean cadence
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Auditory cues at 107.5% of mean cadence
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Auditory cues at 85% of mean cadence
Number of subjects: 11

Group type: COMPARATOR
Intervention: Uncued condition
Number of subjects: 11
Study: 9811282

Group type: EXPERIMENTAL
Intervention: Relaxation training (Group 1)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conversation (Group 2)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Single breast milk sample collection (Group 3)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Self-reported stress
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Success at relaxation (Group 1)
Number of subjects: 38
Study: 7662397

Group type: EXPERIMENTAL
Intervention: Self-help program (printed materials received through the mail)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 171
Study: 2700332

Group type: EXPERIMENTAL
Intervention: Stabilizing splint
Number of subjects: 26

Group type: COMPARATOR
Intervention: Relaxing appliance
Number of subjects: 26
Study: 52001

Group type: EXPERIMENTAL
Intervention: Urokinase
Number of subjects: 341

Group type: COMPARATOR
Intervention: Glucose infusion
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Urokinase and Glucose infusion
Number of subjects: 341
Study: 29246820

Group type: COMPARATOR
Intervention: Standard-dose filgrastim (10 µg/kg BW per day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduced-dose filgrastim (5 µg/kg BW per day)
Number of subjects: 0
Study: 28587974

Group type: EXPERIMENTAL
Intervention: Sitafloxacin
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ertapenem
Number of subjects: 36
Study: 25117722

Group type: EXPERIMENTAL
Intervention: Training session at 02:00 p.m.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Training session at 06:00 p.m.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Training session at 08:00 a.m.
Number of subjects: 9
Study: 23172749

Group type: EXPERIMENTAL
Intervention: Etanercept (ETA) treatment for 1 year
Number of subjects: 40
Study: 22039230

Group type: EXPERIMENTAL
Intervention: Novel contact lenses
Number of subjects: 85

Group type: COMPARATOR
Intervention: Normal, single-vision, spherocylindrical spectacles (Control)
Number of subjects: 85
Study: 18304363

Group type: EXPERIMENTAL
Intervention: Telephone cessation counselling by a trained nurse
Number of subjects: 318

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 318
Study: 16926353

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (333 U/kg initial dose, followed by 250 U/kg every 12 hours)
Number of subjects: 708

Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (100 IU/kg every 12 hours)
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Number of subjects: 708

Group type: COMPARATOR
Intervention: Low-molecular-weight heparin
Number of subjects: 708
Study: 12953129

Group type: EXPERIMENTAL
Intervention: G‐CSF mobilized PB and BM
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: GM‐CSF mobilized BM
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control grafts (unstimulated BM and PB)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: G‐CSF and GM‐CSF mobilized grafts
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: GM‐CSF stimulated BM
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: G‐CSF stimulated PB
Number of subjects: 63
Study: 10899449

Group type: EXPERIMENTAL
Intervention: Catalyzed Signal Amplification system with DYS1 and DYS2 antibodies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control patients with DYS1 and DYS2 antibodies
Number of subjects: 0
Study: 8834701

Group type: EXPERIMENTAL
Intervention: Prolonged mental stress by receiving a letter informing of high screening blood pressure (n = 13)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Neutral letter (n = 13)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups during mental arithmetic
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cold pressor test
Number of subjects: 26
Study: 1563058

Group type: EXPERIMENTAL
Intervention: Sitting position for 15 min after epidural anaesthesia
Number of subjects: 39

Group type: COMPARATOR
Intervention: Supine position during anaesthesia (control group)
Number of subjects: 39
Study: 6609933

Group type: COMPARATOR
Intervention: Oral methylprednisolone 0.5 mg/kg/day for 7 days
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone 1.0 mg/kg (single injection)
Number of subjects: 10
Study: 30098822

Group type: EXPERIMENTAL
Intervention: Combined Manual Therapy (MT) and Diadynamic (DD) currents (MTDD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Manual Therapy (MT) alone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diadynamic (DD) currents alone
Number of subjects: 60
Study: 26787796

Group type: EXPERIMENTAL
Intervention: i-gel SGA
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: laryngeal mask airway supreme (LMAS)
Number of subjects: 615

Group type: COMPARATOR
Intervention: current practice
Number of subjects: 615
Study: 25620452

Group type: EXPERIMENTAL
Intervention: Risk Detection/Executive Function (RD/EF) intervention
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Social Learning/Feminist (SL/F) intervention
Number of subjects: 180
Study: 23992154

Group type: EXPERIMENTAL
Intervention: Special Care Units (SCUs)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Standard beds
Number of subjects: 197
Study: 21909466

Group type: EXPERIMENTAL
Intervention: Injectable calcium sulfate (ICS) graft
Number of subjects: 56

Group type: COMPARATOR
Intervention: Demineralized bone matrix (DBM)‐based graft
Number of subjects: 56
Study: 18201827

Group type: EXPERIMENTAL
Intervention: Ulinastatin (100,000U intravenously three times a day for 1 week)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Ulinastatin (40,000U/kg immediately after burn)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (routine treatment)
Number of subjects: 34
Study: 16968874

Group type: EXPERIMENTAL
Intervention: Epirubicin (E) 110 mg/m2 followed by paclitaxel (P) 250 mg/m2 followed by intensified CMF (cyclophosphamide 840 mg/m2, methotrexate 47 mg/m2 and fluorouracil 840 mg/m2)
Number of subjects: 595

Group type: COMPARATOR
Intervention: Four cycles of Epirubicin (E) followed by four cycles of CMF
Number of subjects: 595
Study: 15882216

Group type: EXPERIMENTAL
Intervention: Transmucosal anaesthetic patches containing lidocaine (46.1 mg/2 cm(2))
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 40